ImpriMed is a precision oncology CRO specializing in ex vivo functional drug sensitivity testing. Our proprietary xCellSense™ platform tests drug candidates directly on live, patient-derived cancer cells. Unlike static genomic profiling, xCellSense™ measures how cancer cells respond to drug candidates in real-time, providing functional response data that predicts actual clinical outcomes. Our services support oncology drug discovery, responder biomarker identification, patient stratification, and combination strategy design for pharma and biotech partners looking to reduce risks before clinical trials. Validated across more than 12,000 naturally occurring blood cancer cases, ImpriMed offers a uniquely proven translational model with a steady supply of primary human-relevant tumor cells.